Advertisement
Screener

NASDAQ:INTS | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | INTENSITY THERAPEUTICS, INC.

0.1 / 5 stars · 3/120 Roast Me

INTENSITY THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect

Financial Statements › Cash Flow

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-11

  • INTENSITY THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$1.68M.
  • INTENSITY THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.66M.
  • INTENSITY THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$1.10M.
  • INTENSITY THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$696.00K.
  • INTENSITY THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $9.33M.
  • INTENSITY THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$5.97M, a 182.36% decline from fiscal 2023.
  • INTENSITY THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $7.24M.
  • INTENSITY THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$3.23M.
Period endCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 monthCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 monthCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filedCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 monthCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filedCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month
2026-06-30-$2.39M
10-Q · filed 2026-08-11
2026-03-31-$1.68M
10-Q · filed 2026-05-07
2025-12-31$9.33M
10-K · filed 2026-03-27
2025-09-30$4.48M
10-Q · filed 2025-11-06
2025-06-30-$374.00K
10-Q · filed 2026-08-11
2025-03-31-$1.66M
10-Q · filed 2026-05-07
2024-12-31-$5.97M
10-K · filed 2026-03-27
2024-09-30-$5.77M
10-Q · filed 2025-11-06
2024-06-30-$5.32M
10-Q · filed 2025-08-07
2024-03-31-$1.10M
10-Q · filed 2025-05-13
2023-12-31$7.24M
10-K · filed 2025-03-13
2023-09-30$5.38M
10-Q · filed 2024-11-13
$5.38M
10-Q · filed 2023-11-13
2023-06-30-$1.18M
10-Q · filed 2024-08-08
-$1.18M
10-Q · filed 2023-08-14
2023-03-31-$696.00K
10-Q · filed 2024-05-09
2022-12-31-$3.23M
10-K · filed 2024-03-14
2022-09-30-$3.84M
10-Q · filed 2023-11-13
2022-06-30-$2.82M
10-Q · filed 2023-08-14